Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches

NCT03885713 is registered in ClinicalTrials.gov with Fundación de Investigación Biomédica - Hospital Universitario de La Princesa as lead sponsor.

NCT NCT03885713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03885713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches
Lead sponsor
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Phase
Phase 4
Overall status
Completed
Start date
September 10, 2019
Completion date
December 31, 2024
Enrollment
180 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

crohn disease, inflammatory bowel diseases, ulcerative colitis